Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportEducational Exhibits

Quality control program to manage metformin stimulated 18-FDG bowel uptake in PET/CT imaging.

Keegan Hovis, Caitlin Moore, Sara Meibom and Gustavo Mercier
Journal of Nuclear Medicine May 2015, 56 (supplement 3) 1951;
Keegan Hovis
2Boston University School of Medicine, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Caitlin Moore
1Radiology - Nuclear Medicine, Boston University Medical Center, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sara Meibom
1Radiology - Nuclear Medicine, Boston University Medical Center, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gustavo Mercier
1Radiology - Nuclear Medicine, Boston University Medical Center, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

1951

Learning Objectives 1. Review the effect of metformin in the GI tract. 2. Illustrate how metformin induced 18-FDG bowel uptake affects the quality of PET/CT imaging and its interpretation. 3. Describe a quick and simple scheme to monitor bowel uptake useful for a quality improvement program. 4. Illustrate the use of the monitoring scheme within a quality improvement program designed to address the problem of metformin induced bowel activity in 18-FDG PET/CT imaging.

Objective: Metformin is an oral hypoglycemic used in the treatment of type 2 diabetes. Use of metformin is associated with increased uptake of 18-FDG in the colon, and to a lesser extent the small bowel. This bowel uptake can be striking, and can mimic malignancies. Hence, it is desirable to manage the degree of bowel uptake in clinical 18-FDG PET/CT through a quality control program. Methods: To do this we developed a program to identify patients taking metformin, stop the medication for 48 hours before injection of 18-FDG, monitor compliance with instructions, and document the expected reductions in bowel uptake by means of a quick but quantitative scheme. We also monitored for hyperglycemia. This educational exhibit provides details of the program and suggestions for its implementation. Results: In our baseline measurements 59% of diabetics were taking metformin, and 86% of these had taken the medication within 24 hours of injection of 18-FDG. Their bowel SUVmax averaged 6.8 gm/ml while diabetics not on metformin had average bowel SUVmax of 3.7 gm/ml. After implementation of the quality control program, 56% of diabetics were on metformin. Sixty-seven percent (67%) stopped taking the medication for at least 48 hours before injection of 18-FDG, and their average SUVmax dropped to 3.6 gm/ml. There were no episodes of significant hyperglycemia. Conclusion: The quality control program reduces 18-FDG bowel uptake in diabetics taking metformin, but compliance with instructions needs improvement.

Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 56, Issue supplement 3
May 1, 2015
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Quality control program to manage metformin stimulated 18-FDG bowel uptake in PET/CT imaging.
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Quality control program to manage metformin stimulated 18-FDG bowel uptake in PET/CT imaging.
Keegan Hovis, Caitlin Moore, Sara Meibom, Gustavo Mercier
Journal of Nuclear Medicine May 2015, 56 (supplement 3) 1951;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Quality control program to manage metformin stimulated 18-FDG bowel uptake in PET/CT imaging.
Keegan Hovis, Caitlin Moore, Sara Meibom, Gustavo Mercier
Journal of Nuclear Medicine May 2015, 56 (supplement 3) 1951;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Educational Exhibits

  • Challenges in F-18 FDG PET/CT: Benign Osseous Hypermetabolic Lesions
  • Do They Work? Utilizing the "Hoshin Kanri" Process in the Nuclear Medicine Department
  • Early small bowel activity may predict rapid gastric transit on gastric emptying scintigraphy
Show more Educational Exhibits

Educational Exhibits Digital Posters Session

  • Imaging Artifacts: A Pictorial Review
  • Musculoskeletal wrist/hand pain: Spectrum of 99mTc-MDP bone SPECT/CT clinical applications & appearances
  • Skeletal muscle metastases: Role of FDG PET/CT imaging and CECT.
Show more Educational Exhibits Digital Posters Session

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire